News

Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceRepligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,…

1 year ago
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO MutationsOcugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

RMAT designation intended to help expedite development of new regenerative medicines MALVERN, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc.…

1 year ago
BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. NetworkBrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network

BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network

BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

1 year ago
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® RoyaltiesXOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties

XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties

Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proceeds expected to be used for stock…

1 year ago
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers SymposiumHarpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel…

1 year ago
Kraig Biocraft Laboratories Announces Successful Production Test Utilizing a Two Strain Hybrid SystemKraig Biocraft Laboratories Announces Successful Production Test Utilizing a Two Strain Hybrid System

Kraig Biocraft Laboratories Announces Successful Production Test Utilizing a Two Strain Hybrid System

ANN ARBOR, Mich., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the…

1 year ago
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseaseuniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to…

1 year ago
Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule TherapeuticsAtavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics

Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics

Proceeds will support lead precision oncology program into the clinic and advance earlier stage pipelineAtavistik Bio is discovering transformative precision…

1 year ago
Appointment of Chief Business OfficerAppointment of Chief Business Officer

Appointment of Chief Business Officer

        19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer Appointment signals…

1 year ago